Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more
Bio-Gene Technology Ltd (BGT) - Total Liabilities
Latest total liabilities as of December 2025: AU$307.71K AUD
Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has total liabilities worth AU$307.71K AUD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bio-Gene Technology Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Bio-Gene Technology Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bio-Gene Technology Ltd Competitors by Total Liabilities
The table below lists competitors of Bio-Gene Technology Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daishin Balance 1
KQ:217270
|
Korea | ₩41.79 Billion |
|
NexPoint Hospitality Trust
V:NHT-U
|
Canada | $179.28 Million |
|
Vivic Corp
OTCQB:VIVC
|
USA | $2.27 Million |
|
TOR Minerals International Inc
PINK:TORM
|
USA | $3.62 Million |
|
Rayong Wire Industries Public Company Limited
BK:RWI
|
Thailand | ฿171.59 Million |
|
Gold By Gold
PA:ALGLD
|
France | €3.39 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
USA | $53.05 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Bio-Gene Technology Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio-Gene Technology Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio-Gene Technology Ltd (2014–2025)
The table below shows the annual total liabilities of Bio-Gene Technology Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$522.98K | +41.94% |
| 2024-06-30 | AU$368.45K | -39.98% |
| 2023-06-30 | AU$613.88K | -40.67% |
| 2022-06-30 | AU$1.03 Million | +37.12% |
| 2021-06-30 | AU$754.57K | +33.01% |
| 2020-06-30 | AU$567.29K | -7.55% |
| 2019-06-30 | AU$613.61K | -19.22% |
| 2018-06-30 | AU$759.59K | +103.13% |
| 2017-06-30 | AU$373.94K | -2.37% |
| 2016-06-30 | AU$383.00K | +40004.71% |
| 2014-06-30 | AU$955.00 | -- |